Conflict of Interest
The author declares the following competing financial interest(s): R.
Khanna is the co-founder of Regulonix LLC, a company developing
non-opioids drugs for chronic pain. In addition, R. Khanna has patents
US10287334 (Non-narcotic CRMP2 peptides targeting sodium channels for
chronic pain) and US10441586 (SUMOylation inhibitors and uses thereof)
issued to Regulonix LLC. R. Khanna and A. Moutal are co-founders of
ElutheriaTx Inc., a company developing gene therapy approaches for
chronic pain.